Gainers

• Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12.94 during Tuesday's regular session. The company's market cap stands at $8.4 million.
• USBC (AMEX:USBC) stock moved upwards by 55.72% to $0.79. The company's market cap stands at $197.1 million.
• Sanara MedTech (NASDAQ:SMTI) shares moved upwards by 30.21% to $23.46. The market value of their outstanding shares is at $165.1 million. As per the news, the Q1 earnings report came out yesterday.
• Alpha Compute (NASDAQ:ALP) shares moved upwards by 28.47% to $0.31. The market value of their outstanding shares is at $5.5 million.
• PACS Group (NYSE:PACS) shares increased by 26.47% to $40.34. The company's market cap stands at $5.0 billion. The company's, Q1 earnings came out yesterday.
• Macrogenics (NASDAQ:MGNX) shares increased by 21.05% to $3.57. The company's market cap stands at $187.4 million.

Losers

• aTyr Pharma (NASDAQ:ATYR) shares fell 27.4% to $0.69 during Tuesday's regular session. The market value of their outstanding shares is at $93.1 million.
• CEL-SCI (AMEX:CVM) stock fell 25.89% to $1.04. The company's market cap stands at $11.9 million.
• WORK Medical Tech Gr (NASDAQ:WOK) shares declined by 25.0% to $2.94.
• Akari Therapeutics (NASDAQ:AKTX) stock fell 24.08% to $3.91. The market value of their outstanding shares is at $184.0 million.
• CVRx (NASDAQ:CVRX) shares fell 22.04% to $5.39. The company's market cap stands at $182.0 million. As per the press release, Q1 earnings came out yesterday.
• Harrow (NASDAQ:HROW) shares declined by 21.88% to $29.72. The company's market cap stands at $1.4 billion. The company's, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.